Home » Stocks » BDTX

Black Diamond Therapeutics, Inc. (BDTX)

Stock Price: $26.14 USD 0.03 (0.11%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $26.05 -0.09 (-0.34%) Jan 22, 7:58 PM
Market Cap 940.93M
Revenue (ttm) n/a
Net Income (ttm) -54.50M
Shares Out 35.93M
EPS (ttm) -13.87
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $26.14
Previous Close $26.11
Change ($) 0.03
Change (%) 0.11%
Day's Open 26.01
Day's Range 25.75 - 26.57
Day's Volume 564,750
52-Week Range 18.18 - 44.80

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 3 days ago

CAMBRIDGE, Mass. and NEW YORK, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development...

GlobeNewsWire - 2 weeks ago

CAMBRIDGE, Mass. and NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development...

GlobeNewsWire - 1 month ago

CAMBRIDGE, Mass. and NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development...

GlobeNewsWire - 2 months ago

CAMBRIDGE, Mass. and NEW YORK, Nov. 20, 2020 (GLOBE NEWSWIRE) --  Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and developmen...

GlobeNewsWire - 2 months ago

CAMBRIDGE, Mass. and NEW YORK, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development...

GlobeNewsWire - 2 months ago

CAMBRIDGE, Mass. and NEW YORK, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development...

GlobeNewsWire - 2 months ago

CAMBRIDGE, Mass. and NEW YORK, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development...

Seeking Alpha - 3 months ago

Black Diamond is an innovative cancer drug-developer using genetic sequencing to identify families of allosteric mutations, and developing drug molecules to inhibit their proliferation. The co...

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass. and NEW YORK, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development...

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass. and NEW YORK, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and developm...

GlobeNewsWire - 4 months ago

CAMBRIDGE, Mass. and NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and developm...

GlobeNewsWire - 4 months ago

Dr. Humphrey brings more than 20 years of experience as a leader in oncology drug development Dr. Humphrey brings more than 20 years of experience as a leader in oncology drug development

GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass. and NEW YORK, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and developme...

Zacks Investment Research - 5 months ago

Black Diamond Therapeutics (BDTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass. and NEW YORK, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and developme...

GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass. and NEW YORK, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and developme...

GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass. and NEW YORK, July 28, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and developme...

GlobeNewsWire - 7 months ago

CAMBRIDGE, Mass. and NEW YORK, June 16, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and developme...

Zacks Investment Research - 8 months ago

Black Diamond Therapeutics (BDTX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

GlobeNewsWire - 8 months ago

CAMBRIDGE, Mass. and NEW YORK, May 12, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and developmen...

Zacks Investment Research - 8 months ago

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

Other stocks mentioned: NERV, SPT, THMO, ZYXI
Zacks Investment Research - 8 months ago

As of late, it has definitely been a great time to be an investor in Black Diamond Therapeutics, Inc. (BDTX).

The Motley Fool - 11 months ago

These four companies just made their debuts. Should they be on your radar?

Other stocks mentioned: ONEM, REYN, ARQT
GlobeNewsWire - 11 months ago

CAMBRIDGE, Mass. and NEW YORK, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and developme...

Benzinga - 11 months ago

Black Diamond Therapeutics (NASDAQ: BDTX) made its public debut Thursday morning, opening at $33 after being priced at $19 per share.

About BDTX

Black Diamond Therapeutics, a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. Its lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR) and tyrosine-protein kinase. The company is also developing allosteric-EGFR mutation inhibitors; and various early stage pipeline programs targeting allosteric mutations in kinases related to cancer and/or rare genetic diseases. The company was formerly known as ASET ... [Read more...]

Industry
Biotechnology
IPO Date
Jan 30, 2020
CEO
Dr. David M. Epstein
Employees
58
Stock Exchange
NASDAQ
Ticker Symbol
BDTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for BDTX stock is "Strong Buy." The 12-month stock price forecast is 50.00, which is an increase of 91.28% from the latest price.

Price Target
$50.00
(91.28% upside)
Analyst Consensus: Strong Buy